BGNE BeiGene, Ltd. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

BGNE [NASD]

BeiGene, Ltd.

Healthcare | Biotechnology | China

statements

Index	-	P/E	-	EPS (ttm)	-18.69	Insider Own	20.53%	Shs Outstand	77.33M	Perf Week	0.09%
Market Cap	16.05B	Forward P/E	-	EPS next Y	-14.75	Insider Trans	-1.02%	Shs Float	59.50M	Perf Month	14.06%
Income	-1208.10M	PEG	-	EPS next Q	-4.77	Inst Own	65.10%	Short Float	4.60%	Perf Quarter	30.34%
Sales	402.40M	P/S	39.88	EPS this Y	-39.00%	Inst Trans	0.06%	Short Ratio	11.89	Perf Half Y	17.07%
Book/sh	36.36	P/B	5.39	EPS next Y	16.80%	ROA	-47.20%	Target Price	199.40	Perf Year	60.21%
Cash/sh	41.22	P/C	4.76	EPS next 5Y	24.00%	ROE	-69.30%	52W Range	114.41 - 210.35	Perf YTD	18.26%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-85.60%	52W High	4.21%	Beta	1.30
Dividend %	-	Quick Ratio	7.90	Sales past 5Y	101.10%	Gross Margin	82.60%	52W Low	91.60%	ATR	7.13
Employees	3600	Current Ratio	8.00	Sales Q/Q	-33.00%	Oper. Margin	-	RSI (14)	76.46	Volatility	3.88% 4.03%
Optionable	Yes	Debt/Eq	0.09	EPS Q/Q	-67.20%	Profit Margin	-	Rel Volume	6.19	Prev Close	196.03
Shortable	Yes	LT Debt/Eq	0.09	Earnings	-	Payout	-	Avg Volume	230.12K	Price	219.21
Recom	1.90	SMA20	17.03%	SMA50	27.55%	SMA200	35.05%	Volume	348,662	Change	11.82%

Jul-10-20

Downgrade

CLSA

Buy → Outperform

Mar-13-20

Upgrade

Macquarie

Underperform → Neutral

Feb-18-20

Resumed

Goldman

Buy

Jan-17-20

Upgrade

CLSA

Outperform → Buy

Jan-17-20

Resumed

Morgan Stanley

Overweight

$210

Dec-16-19

Downgrade

Piper Jaffray

Overweight → Neutral

Dec-16-19

Downgrade

Guggenheim

Buy → Neutral

Nov-19-19

Downgrade

UBS

Buy → Neutral

Nov-13-19

Downgrade

CLSA

Buy → Outperform

Nov-04-19

Reiterated

Maxim Group

Buy

$170 → $210

Jun-04-19

Initiated

Bernstein

Outperform

$201

May-10-19

Upgrade

CLSA

Outperform → Buy

Mar-15-19

Initiated

BofA/Merrill

Buy

$200

Jan-04-19

Downgrade

CLSA

Buy → Outperform

Nov-21-18

Initiated

JP Morgan

Overweight

$174

Sep-25-18

Initiated

Leerink Partners

Outperform

May-17-18

Reiterated

Maxim Group

Buy

$200 → $225

May-14-18

Initiated

Credit Suisse

Outperform

Apr-13-18

Initiated

Piper Jaffray

Overweight

$200

Apr-10-18

Reiterated

Maxim Group

Buy

$160 → $200

Jul-13-20 10:11AM	Amgen (AMGN) Invests Further in China-Based Oncology Partner Zacks +11.82%
07:53AM	Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money Simply Wall St.
06:40AM	Amgen Pours A Further $421M Into Chinas BeiGene SmarterAnalyst
02:03AM	BeiGene Plans $2B Direct Offering; Analyst Sees Further Upside Ahead SmarterAnalyst
Jul-12-20 09:30PM	Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale Bloomberg
08:00PM	BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering GlobeNewswire
Jul-10-20 11:11AM	Insiders Roundup: Mastercard, Eli Lilly GuruFocus.com
Jul-05-20 04:04PM	Is BeiGene, Ltd. (BGNE) A Good Stock To Buy? Insider Monkey
Jul-02-20 07:00AM	BeiGene to Host Investor Conference Call and Webcast to Discuss the Companys Early Development Pipeline and Research GlobeNewswire
Jul-01-20 06:00PM	BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China GlobeNewswire
08:12AM	The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes Benzinga
07:00AM	BeiGene Announces Appointment of Angus Grant as Chief Business Executive GlobeNewswire
Jun-30-20 07:30PM	BeiGene Begins Commercializing XGEVA® (Denosumab) in China GlobeNewswire
Jun-22-20 09:00AM	BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial GlobeNewswire
Jun-19-20 12:27AM	BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China GlobeNewswire
Jun-18-20 07:30AM	BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenströms Macroglobulinemia GlobeNewswire
Jun-12-20 02:30AM	BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress GlobeNewswire
Jun-05-20 07:30AM	BeiGene to Present at the Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire
Jun-03-20 07:15AM	BeiGene Announces the Approval of BRUKINSA (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma GlobeNewswire
May-29-20 08:00AM	BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenströms Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program GlobeNewswire
08:00AM	BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program GlobeNewswire
May-26-20 04:05PM	BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program GlobeNewswire
04:04AM	Chi-Med, BeiGene Join Forces For Solid Cancer Tumor Treatment SmarterAnalyst
02:00AM	Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab GlobeNewswire
May-21-20 07:00AM	BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA (zanubrutinib) in Israel GlobeNewswire
May-20-20 07:00AM	BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference GlobeNewswire
May-15-20 07:00AM	BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II GlobeNewswire
May-14-20 05:45PM	Growth Stocks Like Amazon And Tesla Share These Key Metrics: Advisor Investor's Business Daily
09:00AM	BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress GlobeNewswire
May-11-20 04:05PM	BeiGene Reports First Quarter 2020 Financial Results GlobeNewswire
Apr-29-20 05:00PM	BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
Apr-20-20 04:05PM	BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China GlobeNewswire
Apr-13-20 04:05PM	BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis GlobeNewswire
Apr-10-20 06:00PM	China National Medical Products Administration Approves BeiGenes Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma GlobeNewswire
Mar-26-20 02:30PM	ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. Business Wire
Mar-25-20 09:00AM	BeiGene Announces Supply Update for ABRAXANE® in China GlobeNewswire -5.75%
Mar-19-20 05:09PM	Hedge Funds Are Betting On BeiGene, Ltd. (BGNE) Insider Monkey
Mar-10-20 12:57PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Mar-09-20 12:30PM	ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire
Mar-07-20 10:31AM	Coronavirus Outbreak Could Disrupt Drug Companies Clinical Trials Barrons.com
Mar-02-20 04:05PM	BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-27-20 07:14AM	MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors GlobeNewswire
Feb-25-20 07:00AM	BeiGene to Present at the Cowen and Companys 40th Annual Health Care Conference GlobeNewswire
Feb-18-20 10:49AM	Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's new sr. unsecured notes; stable outlook Moody's
Jan-21-20 07:00AM	BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis GlobeNewswire
Jan-13-20 07:00AM	EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA® in Greater China GlobeNewswire
Jan-08-20 07:30AM	BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-06-20 08:25AM	Leap Therapeutics Surges on License Agreement With BieGene Zacks
Jan-03-20 02:11PM	Cash-strapped biotech signs deal with Chinese drugmaker BeiGene American City Business Journals
08:53AM	Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing PR Newswire
Jan-02-20 08:15AM	BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment GlobeNewswire
Dec-30-19 05:17PM	BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China Zacks
Dec-28-19 09:30AM	ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire
Dec-27-19 10:30PM	China National Medical Products Administration Approves BeiGenes Tislelizumab for Patients with Classical Hodgkins Lymphoma Who Have Received at Least Two Prior Therapies GlobeNewswire
Dec-22-19 06:00PM	BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent Lymphoma GlobeNewswire
Dec-20-19 09:25AM	Key AbbVie Drug Faces Competition Worries After Head-to-Head Study Barrons.com
Dec-19-19 04:40PM	These Hedge Funds Cashed Out Of BeiGene, Ltd. (BGNE) Too Early Insider Monkey
Dec-16-19 07:00AM	BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenströms Macroglobulinemia GlobeNewswire -6.21%
Dec-13-19 07:00AM	BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019 GlobeNewswire
Dec-08-19 04:45PM	BeiGene Announces Clinical Data on BRUKINSA (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Dec-02-19 06:02PM	SK Biopharmaceuticals IPO Tabbed to Raise $850 Million GuruFocus.com
Nov-29-19 03:30PM	BGNE LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire
Nov-26-19 05:54PM	BeiGene Shares Climb Nearly 50% After Amgen Deal GuruFocus.com
07:00AM	BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-23-19 05:00AM	BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress GlobeNewswire
Nov-16-19 08:43AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE ACCESSWIRE
Nov-15-19 05:34PM	BeiGene prices lymphoma drug at $12,935 for a 30-day supply Reuters
10:09AM	The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval Benzinga
04:30AM	Stocks Blog: AAC Technologies, BeiGene jump; Hang Seng Index rises as traders look for bargains South China Morning Post
02:00AM	US regulator issues first approval for a Chinese cancer treatment Financial Times
Nov-14-19 04:20PM	U.S. FDA Grants BeiGenes BRUKINSA (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy GlobeNewswire
04:01PM	UPDATE 2-China's BeiGene gets FDA approval for drug to treat rare form of lymphoma Reuters
03:49PM	BeiGene drug wins U.S. FDA approval for rare form of lymphoma Reuters
Nov-13-19 03:11PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE GlobeNewswire
Nov-12-19 04:05PM	BeiGene Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-11-19 06:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE ACCESSWIRE
Nov-10-19 07:00PM	ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire
Nov-07-19 05:54PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE GlobeNewswire
Nov-06-19 10:58AM	Bragar Eagel & Squire, P.C. Is Investigating Merit Medical Systems, Baxter International, Under Armour, and BeiGene on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
09:00AM	BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting GlobeNewswire
Nov-05-19 10:13AM	The Zacks Analyst Blog Highlights: Navient, BeiGene, SPS Commerce and Chipotle Mexican Grill Zacks
08:00AM	Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate Business Wire
Nov-04-19 11:18AM	AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates Zacks
07:56AM	4 Stocks to Buy From Sectors With Maximum Job Gains Zacks
Nov-01-19 06:12PM	BEIGENE ALERT: Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire +37.02%
03:18PM	Biotech ETFs Strengthen as Amgen Invests in Chinas BeiGene ETF Trends
02:49PM	Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance Zacks
02:40PM	Amgen Inc. -- Moody's: Amgen's BeiGene collaboration will expand geographic reach but reduce cash Moody's
07:38AM	The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance Benzinga
04:53AM	Amgen to Take $2.7 Billion Stake in BeiGene for China Growth Bloomberg
03:01AM	Jobs Report, Exxon, Pinterest, Amgen, U.S. Steel - 5 Things You Must Know Friday TheStreet.com
Oct-31-19 05:28PM	Amgen Is Taking A $2.7 Billion Stake In A Chinese Biotech Here's Why Investor's Business Daily
04:00PM	BeiGene Announces Global Strategic Oncology Collaboration with Amgen GlobeNewswire
03:49PM	[video]Amgen Takes $2.7 Billion Stake in BeiGene to Expand Access to China TheStreet.com
07:54AM	Have Insiders Been Selling BeiGene, Ltd. (NASDAQ:BGNE) Shares? Simply Wall St.
Oct-30-19 10:00AM	BeiGene, Ltd. (BGNE) is a Great Momentum Stock: Should You Buy? Zacks
Oct-29-19 08:02PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud: Investors Who Suffered Losses Encouraged to Contact Firm GlobeNewswire
Oct-28-19 03:30PM	ROSEN, A HIGHLY RANKED LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE Business Wire
Oct-23-19 04:50PM	ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:30AM	Were Hedge Funds Right About Dumping BeiGene, Ltd. (BGNE)? Insider Monkey

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; and Hutchison China MediTech Limited. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OYLER JOHN	Chief Executive Officer	Jul 08	Sale	201.39	17,529	3,530,206	0	Jul 08 05:20 PM
Huang Jane	CMO, Hematology	Jul 07	Option Exercise	160.40	3,921	628,928	3,921	Jul 09 04:43 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jul 07	Sale	200.00	6,000	1,200,000	0	Jul 09 04:45 PM
Huang Jane	CMO, Hematology	Jul 07	Sale	200.00	3,921	784,200	0	Jul 09 04:43 PM
OYLER JOHN	Chief Executive Officer	Jul 07	Sale	198.86	19,023	3,782,987	0	Jul 08 05:20 PM
OYLER JOHN	Chief Executive Officer	Jul 06	Sale	197.11	17,362	3,422,262	0	Jul 08 05:20 PM
OYLER JOHN	Chief Executive Officer	Jul 01	Sale	191.57	3,816	731,016	0	Jul 01 04:43 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jul 01	Sale	190.75	4,847	924,572	0	Jul 06 04:52 PM
Huang Jane	CMO, Hematology	Jun 29	Option Exercise	29.49	1,500	44,235	1,500	Jun 30 04:14 PM
OYLER JOHN	Chief Executive Officer	Jun 29	Sale	192.60	1,435	276,374	0	Jul 01 04:43 PM
Liang Howard	CFO & Chief Strategy Officer	Jun 29	Sale	191.23	300	57,368	0	Jul 01 04:38 PM
Huang Jane	CMO, Hematology	Jun 29	Sale	190.83	1,935	369,250	0	Jun 30 04:14 PM
Huang Jane	CMO, Hematology	Jun 26	Option Exercise	160.40	2,079	333,472	2,079	Jun 30 04:14 PM
Huang Jane	CMO, Hematology	Jun 26	Sale	200.29	2,079	416,397	0	Jun 30 04:14 PM
OYLER JOHN	Chief Executive Officer	Jun 24	Sale	187.34	14,381	2,694,156	0	Jun 24 08:23 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 23	Sale	186.38	6,000	1,118,298	0	Jun 24 08:12 PM
OYLER JOHN	Chief Executive Officer	Jun 23	Sale	186.88	15,070	2,816,222	14,381	Jun 24 08:23 PM
OYLER JOHN	Chief Executive Officer	Jun 22	Sale	182.43	10,281	1,875,605	29,451	Jun 24 08:23 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 22	Sale	181.33	5,000	906,673	0	Jun 24 08:12 PM
OYLER JOHN	Chief Executive Officer	Jun 10	Sale	175.07	900	157,563	0	Jun 12 04:14 PM
Liang Howard	CFO & Chief Strategy Officer	Jun 08	Sale	170.84	453	77,391	0	Jun 10 05:17 PM
Wu Xiaobin	President & GM China	Jun 08	Sale	170.83	2,800	478,317	0	Jun 10 05:15 PM
Huang Jane	CMO, Hematology	Jun 08	Sale	170.84	631	107,800	0	Jun 10 05:13 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 08	Sale	170.91	6,000	1,025,455	0	Jun 10 05:12 PM
Huang Jane	CMO, Hematology	May 29	Option Exercise	29.49	1,500	44,235	1,500	Jun 02 04:11 PM
Huang Jane	CMO, Hematology	May 29	Sale	163.86	1,500	245,784	0	Jun 02 04:11 PM
Glazer Donald W.	Director	May 19	Sale	169.84	10,000	1,698,400	0	May 21 04:08 PM
OYLER JOHN	Chief Executive Officer	May 01	Sale	141.43	4,635	655,537	0	May 05 04:48 PM
Wu Xiaobin	President & GM China	May 01	Sale	141.33	7,024	992,711	0	May 05 04:46 PM
Huang Jane	CMO, Hematology	Apr 29	Option Exercise	29.49	1,500	44,235	1,500	Apr 30 04:04 PM
Huang Jane	CMO, Hematology	Apr 29	Sale	162.30	1,500	243,450	0	Apr 30 04:04 PM
Huang Jane	CMO, Hematology	Apr 16	Option Exercise	29.49	1,500	44,235	1,500	Apr 17 04:04 PM
Huang Jane	CMO, Hematology	Apr 16	Sale	160.00	1,500	240,000	0	Apr 17 04:04 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Mar 04	Sale	157.14	5,000	785,681	0	Mar 06 08:30 PM
Huang Jane	CMO, Hematology	Feb 18	Option Exercise	29.49	1,500	44,235	1,500	Feb 20 04:13 PM
Huang Jane	CMO, Hematology	Feb 18	Sale	170.25	1,500	255,380	0	Feb 20 04:13 PM
Huang Jane	CMO, Hematology	Jan 21	Option Exercise	29.49	1,500	44,235	1,500	Jan 22 06:59 PM
Huang Jane	CMO, Hematology	Jan 21	Sale	170.69	1,500	256,042	0	Jan 22 06:59 PM
OYLER JOHN	Chief Executive Officer	Dec 17	Sale	160.62	62,259	10,000,100	0	Dec 19 04:10 PM
Huang Jane	CMO, Hematology	Dec 16	Option Exercise	29.49	1,500	44,235	1,500	Dec 18 06:57 PM
Huang Jane	CMO, Hematology	Dec 16	Sale	165.14	1,500	247,710	0	Dec 18 06:57 PM
Huang Jane	CMO, Hematology	Nov 18	Option Exercise	29.49	1,500	44,235	1,500	Nov 20 07:19 PM
Liang Howard	CFO & Chief Strategy Officer	Nov 18	Option Exercise	6.50	25,000	162,500	25,000	Nov 20 07:20 PM
Liang Howard	CFO & Chief Strategy Officer	Nov 18	Sale	194.34	25,000	4,858,616	0	Nov 20 07:20 PM
Huang Jane	CMO, Hematology	Nov 18	Sale	194.49	1,500	291,740	0	Nov 20 07:19 PM
Wu Xiaobin	President & GM China	Nov 15	Sale	202.05	1,000	202,050	0	Nov 18 05:22 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 15	Sale	202.05	395	79,810	0	Nov 18 05:24 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 15	Sale	202.05	1,496	302,267	0	Nov 18 05:24 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 14	Sale	193.57	2,605	504,242	395	Nov 18 05:24 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 14	Sale	193.31	8,504	1,643,880	1,496	Nov 18 05:24 PM
Chen Timothy Yung-Cheng	Director	Nov 05	Option Exercise	41.01	4,000	164,040	4,000	Nov 06 06:50 PM
Chen Timothy Yung-Cheng	Director	Nov 05	Sale	189.15	3,800	718,772	200	Nov 06 06:50 PM
Chen Timothy Yung-Cheng	Director	Nov 04	Option Exercise	41.01	4,000	164,040	4,000	Nov 06 06:50 PM
Huang Jane	CMO, Hematology	Nov 04	Option Exercise	29.49	32,900	970,221	32,900	Nov 06 06:51 PM
Huang Jane	CMO, Hematology	Nov 04	Sale	190.46	32,900	6,266,007	0	Nov 06 06:51 PM
Chen Timothy Yung-Cheng	Director	Nov 04	Sale	190.49	4,200	800,073	0	Nov 06 06:50 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 04	Sale	190.00	1,000	190,000	0	Nov 05 04:22 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 01	Sale	170.00	1,000	170,000	0	Nov 05 04:22 PM
Wu Xiaobin	President & GM China	Nov 01	Sale	180.00	1,000	180,000	0	Nov 05 04:20 PM
Huang Jane	CMO, Hematology	Sep 04	Sale	129.40	82	10,611	0	Sep 05 08:15 PM
Huang Jane	CMO, Hematology	Sep 03	Sale	144.45	2,862	413,420	0	Sep 05 08:15 PM
Chen Timothy Yung-Cheng	Director	Aug 23	Option Exercise	31.59	7,900	249,561	7,900	Aug 27 04:04 PM
Chen Timothy Yung-Cheng	Director	Aug 23	Sale	144.96	8,614	1,248,680	0	Aug 27 04:04 PM
Huang Jane	CMO, Hematology	Aug 12	Option Exercise	45.31	2,500	113,275	2,500	Aug 13 04:47 PM
Huang Jane	CMO, Hematology	Aug 12	Sale	134.74	2,500	336,855	0	Aug 13 04:47 PM
Huang Jane	CMO, Hematology	Jul 29	Option Exercise	37.30	10,130	377,834	10,130	Jul 31 04:04 PM
Huang Jane	CMO, Hematology	Jul 29	Sale	134.54	10,130	1,362,896	0	Jul 31 04:04 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience